

**ALKEM LABORATORIES LTD.**

Regd. Office : ALKEM HOUSE, Senapati Bapat Marg,
Lower Parel (West), Mumbai - 400 013, Maharashtra, India.

• Phone: +91-22-3982 9999 • Fax: 022-2495 2955
• Email: contact@alkem.com • Website: www.alkemlabs.com
• CIN: L00305MH1973PLC174201

27th September, 2024

To,

**The Corporate Relationship Department
BSE Limited**
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai 400 001.
Scrip Code: 539523

National Stock Exchange of India Limited
Exchange Plaza,
Bandra Kurla Complex,
Bandra East ,
Mumbai 400 051.
Scrip Symbol: ALKEM

Sub: Press Release – ALKEM denies claims of Pan-D, Clavam 625 batches being not-of-standard quality.

Dear Sir(s)/Madam,

This is to intimate you that the Company denies claims of Pan-D, Clavam 625 batches being not-of-standard quality. A press release in this regard is enclosed herewith.

Kindly take the same on record.

Sincerely,
For **Alkem Laboratories Limited**

Manish Narang
President- Legal, Company Secretary and Compliance Officer

Press Release

Alkem Laboratories denies claims of Pan-D, Clavam 625 batches being not-of-standard quality

- *The samples of both products mentioned in the CDSCO list are spurious and not manufactured by Alkem*
- *Alkem gives utmost importance to quality and patient safety. All products manufactured at our sites follow the current good manufacturing practices (cGMP)*

Mumbai, September 27, 2024: Alkem Laboratories Ltd. (BSE: 539523, NSE: ALKEM, “Alkem” and includes its associate companies and/or subsidiaries), denies claims that batches of its products Pan-D and Clavam 625 are not-of-standard quality (NSQ), as reported by several media publications and channels based on a list issued by the Central Drugs Standard Control Organization (CDSCO).

The media reports refer to the CDSCO East Zone, Kolkata’s update that mentioned one batch of Pan-D capsules (Batch No. #23444296) and one batch of Clavam 625 tablets (Batch No. #23443940), among many other drugs of other pharmaceutical companies, as allegedly being not-of-standard quality.

Alkem conducted a thorough investigation by comparing the samples collected by the CDSCO with the actual batches of both products manufactured by Alkem and found that the samples picked by the CDSCO were spurious and not manufactured by Alkem. The conclusion is based on the differences observed between the CDSCO samples and the actual batches manufactured by Alkem in terms of physical appearance, colour and text in the labelling of the two products. Alkem has already submitted a response to the CDSCO, along with the assessment report which confirmed that samples collected by CDSCO are spurious and not manufactured by Alkem.

Alkem remains committed to following the highest quality standards and the current good manufacturing practices (cGMP) for all its products. To tackle the spurious drugs issues, Alkem has incorporated unique features and QR codes in its packaging of both Pan-D and Clavam 625, which separates the genuine products from the spurious ones.

About Alkem:

Alkem Laboratories Ltd. is a leading Indian pharmaceutical company with a legacy of 50 years in providing high quality medicines to patients. It is the fifth largest pharmaceutical company in the Indian market with a dominant position in the therapy areas of anti-infectives, gastrointestinal, pain management drugs and supplements. It also has a growing portfolio of products in chronic therapies such as diabetes, neurology, cardiology, dermatology and urology. It has 19 state-of-the-art manufacturing facilities and cutting-edge research and development (R&D) centers across India and the US to develop and manufacture generic formulations, active pharmaceutical ingredients (APIs) and biosimilars. Apart from India, the company has meaningful presence in the US, Latin America, Australia and several Asian countries. “Inspiring Healthier Lives” is at the core of the values and culture of the organisation and reinforces its steadfast commitment to global health improvement. For more information, please visit www.alkemlabs.com and follow us on [LinkedIn](#), [X](#), [Facebook](#), [Instagram](#).

Contacts	
Media: Isha Trivedi/Richa Kedar Sinari alkemcorpcomm@alkem.com +91-98925 90003	Investors: Purvi Shah purvi.shah@alkem.com +91-84337 00890